Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.67 | N/A | +17.19% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.67 | N/A | +17.19% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed confidence in their product pipeline and emphasized the importance of innovation. They also acknowledged market challenges.
Management highlighted strong performance in key therapeutic areas.
They noted ongoing investments in R&D to drive future growth.
Amgen's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell slightly by 0.55%, likely due to the lack of revenue information and guidance. Investors may be cautious given the absence of forward-looking statements.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CANADIAN NATL RY CO
Oct 22, 2012